DIscontinuation of Anticoagulation MONitoreD by Smartwatch Versus Continuous Anticoagulation in Post-ablation Patients With Atrial Fibrillation: A Randomized Controlled Trial
The DIAMOND-AF trial, an investigator-initiated multicenter study, randomizes 5,694 stroke-free AF patients with a CHA₂DS₂-VA score of 2-6 post-successful ablation to either smartwatch-guided intermittent direct oral anticoagulant (DOAC) therapy (30-day treatment triggered by AF episodes ≥1 hour single or ≥2 hours/24h) or continuous DOAC therapy. The trial assesses the superiority of intermittent DOAC therapy in reducing major bleeding (ISTH) compared to continuous DOAC therapy, and the non-inferiority of intermittent DOAC in preventing thromboembolism (stroke, embolism, and cardiovascular death) over a 48-month follow-up, aiming to tailor anticoagulation strategies in patients with rhythm control achieved through ablation.
• Age 18-80 years.
• No recurrence of atrial arrhythmia within 3 months after the most recent AF/atrial flutter catheter ablation.
• CHA₂DS₂-VA score of 2-6.
• Voluntarily sign informed consent to participate in the study.
• Willingness and ability to comply with the study protocol.